K&E, Skadden led on Clover Biopharmaceuticals’ $260mln IPO in Hong Kong

Kirkland & Ellis and Tian Yuan Law Firm have advised Clover Biopharmaceuticals on its $260 million IPO in Hong Kong, with Skadden, Arps, Slate, Meagher & Flom and Commerce & Finance Law Offices advising the joint underwriters.

Established in 2007, the Cayman Island-registered Clover Biopharmaceuticals focuses on developing new vaccines and biological treatments for infectious diseases, cancer, and autoimmune diseases.

The K&E team was led by partners Lu Mengyu who was assisted by partner Peng Bo.

The joint underwriters were Goldman Sachs and CICC. Maples and Calder served as the issuer’s offshore lawyer.


To contact the editorial team, please email